Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients
文献类型：期刊论文
| 作者 | Hao, Yue3,4; Lin, Gen5; Xiang, Jing4; Wang, Wenxian4; Xu, Chunwei6; Wang, Qian1; Cai, Jing7; Zhang, Yongchang2; Song, Zhengbo4 |
| 刊名 | CANCER MEDICINE
 |
| 出版日期 | 2022-11-16 |
| 关键词 | efficacy immune-related adverse events immunotherapy thymoma |
| ISSN号 | 2045-7634 |
| DOI | 10.1002/cam4.5357 |
| 通讯作者 | Song, Zhengbo(songzb@zjcc.org.cn) |
| 英文摘要 | Background Immunotherapy has exhibited efficacy in thymic carcinoma patients; however, there are insufficient data to confirm this efficacy in thymoma. The toxicity of immunotherapy also remains to be determined. Methods The efficacy and safety of immunotherapy were analyzed in 11 thymoma patients who received PD-1 inhibitors according to a range of relevant indexes including the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and immunotherapy-related adverse events. Results The PFS and OS rates for all patients were 12.8 and 56.5 months, respectively. No difference in efficacy was detected between monotherapy and combination therapy (PFS: 12.8 vs 2.2 months, P = 0.787; OS: 73.8 vs 56.5 months, P = 0.367). The ORRs and DCRs for all patients were 27.3% and 90.9%, respectively. The incidence of adverse events was 45.5% among the 11 thymoma patients, including immune-related myocarditis (36.4%), immune-related liver damage (18.2%), and myasthenia gravis (18.2%). In the whole cohort of patients, the rate of adverse events of grade 3 or higher was 36.4%. The rates of adverse events of grade 3 or 4 in B3-type and non-B3-type thymoma patients were 0% and 62.5%, respectively. Conclusions Immunotherapy elicited a response in thymoma patients; however, more attention should be paid to the immune-related adverse events. |
| WOS关键词 | THYMIC CARCINOMA ; PEMBROLIZUMAB ; CHEMOTHERAPY ; CISPLATIN |
| 资助项目 | Foundation of CSCO-Shiyao[Y-SY201901-0068] ; Zhejiang provincial program for the Cultivation of High-level Innovative Health talents |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:000884642300001 |
| 出版者 | WILEY |
| 资助机构 | Foundation of CSCO-Shiyao ; Zhejiang provincial program for the Cultivation of High-level Innovative Health talents |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/130295]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Song, Zhengbo |
| 作者单位 | 1.Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Affiliated Hosp, Dept Resp Med, Nanjing, Peoples R China 2.Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp,Dept Med Oncol, Hunan Canc Hosp,Lung Canc & Gastrointestinal Unit, Changsha, Peoples R China 3.Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Zhejiang, Peoples R China 4.Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Zhejiang Canc Hosp, Hangzhou, Peoples R China 5.Fujian Med Univ Canc Hosp, Dept Thorac Oncol, Fujian Canc Hosp, Fuzhou, Peoples R China 6.Nanjing Univ, Dept Resp Med, Jinling Hosp, Sch Med, Nanjing, Peoples R China 7.Nanchang Univ, Dept Oncol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China |
| 推荐引用方式 GB/T 7714 | Hao, Yue,Lin, Gen,Xiang, Jing,et al. Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients[J]. CANCER MEDICINE,2022. |
| APA | Hao, Yue.,Lin, Gen.,Xiang, Jing.,Wang, Wenxian.,Xu, Chunwei.,...&Song, Zhengbo.(2022).Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients.CANCER MEDICINE. |
| MLA | Hao, Yue,et al."Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients".CANCER MEDICINE (2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。